Mark Corrigan
Directeur/Membre du Conseil chez TREVENA, INC.
Fortune : 409 $ au 31/05/2024
Profil
Mark H.
N.
Corrigan was the founder of Tremeau Pharmaceuticals, Inc. (founded in 2016) where he held the title of President-Research & Development.
He is currently the Chairman at Exacis Biotherapeutics, Inc. (since 2020), an Independent Director at Wave Life Sciences Ltd.
(since 2019), an Independent Director at Trevena, Inc. (since 2023), a Director at Pamlico BioPharma, Inc., a Director at Wave Life Sciences USA, Inc. (since 2019), a Director at Perseus Holdings USA LLC (since 2020), a Scientific Advisor at Brighton Biotech, Inc., and the President at Silver Creek Pharmaceuticals, Inc. (since 2024).
Dr. Corrigan's former positions include being the Chief Executive Officer & Director at Correvio Pharma Corp.
(2015-2020), the President & Chief Executive Officer at CombinatoRx, Inc. (2009-2010), the President, Chief Executive Officer & Director at Zalicus, Inc. (2009-2014), the Chairman at EPIRUS Biopharmaceuticals, Inc. (2009-2016), the Executive Chairman at Novelion Therapeutics, Inc. (2017-2019), an Independent Director at Cubist Pharmaceuticals LLC (2008-2015), an Independent Director at Avanir Pharmaceuticals, Inc. (2014-2015), a Director at CoLucid Pharmaceuticals, Inc. (2015-2017), a Lead Independent Director at BlackThorn Therapeutics, Inc. (2015-2019), an Independent Director at Nabriva Therapeutics Plc (2017-2020), an Independent Director at Nabriva Therapeutics Plc (2021-2023), the Group Vice President-Global Clinical Research at Pharmacia & Upjohn, Inc. (1993-2003), the Executive Vice President-Research & Development at Sumitomo Pharma America, Inc. (2003-2009), the Group Vice President-Global Clinical Research at Pharmacia Corp.
(1998-2003), a Member-Supervisory Board at Nabriva Therapeutics GmbH (2016-2017), and a Principal at UNC School of Medicine.
Dr. Corrigan obtained his undergraduate and doctorate degrees from the University of Virginia.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
NABRIVA THERAPEUTICS PLC
0,01% | 31/01/2023 | 288 ( 0,01% ) | 409 $ | 31/07/2023 |
WAVE LIFE SCIENCES LTD.
-.--% | 27/03/2024 | 0 ( -.--% ) | - $ | 31/05/2024 |
Postes actifs de Mark Corrigan
| Sociétés | Poste | Début |
|---|---|---|
| WAVE LIFE SCIENCES LTD. | Directeur/Membre du Conseil | 04/09/2019 |
| TREVENA, INC. | Directeur/Membre du Conseil | 18/07/2023 |
Wave Life Sciences USA, Inc.
 Wave Life Sciences USA, Inc. Electric UtilitiesUtilities Part of Wave Life Sciences Ltd., Wave Life Sciences USA, Inc. is a company that provides nucleic acid therapeutics. The company is based in Cambridge, MA. The company was founded in 2012 by Gregory L. Verdine, Takeshi Wada. The CEO is Paul B. Bolno. | Directeur/Membre du Conseil | 01/09/2019 |
Exacis Biotherapeutics, Inc.
 Exacis Biotherapeutics, Inc. Medical/Nursing ServicesHealth Services Part of Eterna Therapeutics, Inc., Exacis Biotherapeutics, Inc. is a development stage immuno-oncology company based in Cambridge, MA. Exacis uses its proprietary-based technologies to engineer next generation off-the-shelf NK and T cell therapies aimed at liquid and solid tumors. Exacis has an exclusive license to the Factor Bioscience technology for engineered NK and T cell products derived from iPSCs for use in oncology and holds all development and commercial rights for these investigational candidates. Exacis' approach avoids the use of DNA and viruses and instead uses a proprietary-based technology to generate iPSCs and to edit their genome to create stealthed, performance-enhanced allogeneic NK and T cell products, termed ExANK™, Exacar-NK™, and Exacar-T™ cells. The company was founded in 2020 by Gregory Fiore, Matthew Angel, James Pan. Gregory Fiore has been the CEO since 2020. Exacis Biotherapeutics was acquired by Eterna Therapeutics, Inc. on May 02, 2023 for $49 million. | Président | 01/08/2020 |
Perseus Holdings USA LLC
 Perseus Holdings USA LLC Electronics DistributorsDistribution Services Perseus Holdings USA LLC markets vaccine platform technology. The company is headquartered in Austin, TX. | Directeur/Membre du Conseil | 20/10/2020 |
Brighton Biotech, Inc.
 Brighton Biotech, Inc. BiotechnologyHealth Technology Brighton Biotech, Inc. provides medical research services. It specializes in acquiring and developing pharmaceutical and biotechnology products intended for the treatment and prevention of serious unmet medical needs. The company was founded in 2010 and is headquartered in New York, NY. | Corporate Officer/Principal | - |
Pamlico BioPharma, Inc.
 Pamlico BioPharma, Inc. BiotechnologyHealth Technology Pamlico BioPharma, Inc. provides antibody therapeutics services. It develops fully-human monoclonal antibody (hmAb) therapeutics for the rapid diagnosis and treatment of infectious diseases and cancer. The firms lead program is focused on severe pneumonia caused by streptococcus pneumoniae (SPN), and is in preclinical IND-directed activities for a mAb cocktail and a companion point-of-care (POC) diagnostic against three serotypes that account for over 40% of SPN infections. The company was founded on 18 December, 2014 and is headquartered in Oklahoma, OK. | Directeur/Membre du Conseil | - |
Silver Creek Pharmaceuticals, Inc.
 Silver Creek Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Silver Creek Pharmaceuticals, Inc. develops novel regenerative medicines. The firm focuses on treating cardiovascular disease. Its molecules are designed to promote resilience and regeneration of damaged tissues after acute or chronic injury. The company was founded in 2010 and is headquartered in San Francisco, CA. | President | 12/02/2024 |
Anciens postes connus de Mark Corrigan
| Sociétés | Poste | Fin |
|---|---|---|
| NABRIVA THERAPEUTICS PLC | Directeur/Membre du Conseil | 30/07/2023 |
| ░░░░░░░░ ░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Mark Corrigan
| University of Virginia | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| EPIRUS BIOPHARMACEUTICALS, INC. | Health Technology |
| NABRIVA THERAPEUTICS PLC | Health Technology |
| WAVE LIFE SCIENCES LTD. | Health Technology |
| TREVENA, INC. | Health Technology |
| Entreprise privées | 23 |
|---|---|
Sumitomo Pharma America, Inc.
 Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Health Technology |
Pamlico BioPharma, Inc.
Pamlico BioPharma, Inc. BiotechnologyHealth Technology Pamlico BioPharma, Inc. provides antibody therapeutics services. It develops fully-human monoclonal antibody (hmAb) therapeutics for the rapid diagnosis and treatment of infectious diseases and cancer. The firms lead program is focused on severe pneumonia caused by streptococcus pneumoniae (SPN), and is in preclinical IND-directed activities for a mAb cocktail and a companion point-of-care (POC) diagnostic against three serotypes that account for over 40% of SPN infections. The company was founded on 18 December, 2014 and is headquartered in Oklahoma, OK. | Health Technology |
Pharmacia Corp.
 Pharmacia Corp. Pharmaceuticals: MajorHealth Technology Pharmacia Corp. developed, manufactured and marketed pharmaceutical products. Prescription pharmaceuticals included general therapeutics, ophthalmology and hospital products including oncology and diversified therapeutics. It also operated in consumer health care, animal health, diagnostics and contract manufacturing and bulk pharmaceutical chemicals. The customers of the group were pharmacies, hospitals, chain warehouses, governments, physicians, wholesalers and other distributors. It was headquartered in Peapack, NJ. | Health Technology |
Cubist Pharmaceuticals LLC
 Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cubist Pharmaceuticals LLC operates as a biopharmaceutical company. It focuses on the research, development and commercialization of pharmaceutical products. The company was founded in 1992 and is headquartered in Lexington, MA. | Health Technology |
CombinatoRx, Inc.
 CombinatoRx, Inc. Pharmaceuticals: OtherHealth Technology CombinatoRx, Inc. develops new medicines built from synergistic combinations of approved drugs. The company develops biopharmaceutical products. It conducts clinical trials and research programs. The company was founded by Alexis Borisy, Brent R. Stockwell, Michael A. Foley, Curtis T. Keith and Jacob D. Goldfield in 2000 and is headquartered in Cambridge, MA | Health Technology |
Zalicus, Inc.
 Zalicus, Inc. Pharmaceuticals: MajorHealth Technology Zalicus, Inc. is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain. The company develops Z944, a novel oral T-type calcium channel blocker that has completed Phase Ib clinical studies for the treatment of pain indications. It is also engaged in research and preclinical development activities on its selective ion channel modulators targeting the Nav1.7 sodium channel for the treatment of pain. The company changed its name from CombinatoRx, Inc. to Zalicus, Inc. on September 8, 2010. Zalicus was founded on March 28, 2000 and is headquartered in Cambridge, MA. | Health Technology |
| Pharmacia & Upjohn, Inc. | Health Technology |
Avanir Pharmaceuticals, Inc.
 Avanir Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Avanir Pharmaceuticals, Inc. engages in the development of therapeutic products for the treatment of nervous system disorder. The company was founded on August 31, 1988 and headquartered in Aliso Viejo, CA. | Health Technology |
Synereca Pharmaceuticals, Inc.
 Synereca Pharmaceuticals, Inc. Medical DistributorsDistribution Services Synereca Pharmaceuticals, Inc. develops orally active drugs that restore the effectiveness of existing antibiotics. It focuses on compounds that enhance the activity of Colistin against gram-negative bacteria without enhancing its toxicity. The company was founded in 2009 by Clayton I. Duncan, Stephen B. Bocckino and Bennett W. Love and is headquartered in Oklahoma City, OK. | Distribution Services |
Correvio Pharma Corp.
 Correvio Pharma Corp. Pharmaceuticals: MajorHealth Technology Correvio Pharma Corp. operates as a pharmaceutical company, which engages in the provision of development and commercialization of medical products. It operates through the Europe and Rest of the World geographical segments. The firm focuses on cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease. It offers the Brinavess and Aggrastat products to customers such as physicians, patients and healthcare systems. The company was founded in 1986 and is headquartered in Vancouver, Canada. | Health Technology |
Quartet Medicine, Inc.
 Quartet Medicine, Inc. BiotechnologyHealth Technology Quartet Medicine, Inc. is a biotechnology company that develops treatments for chronic pain and inflammation by restoring tetrahydrobiopterin homeostasis inneuronal and inflammatory cells. Its drug discovery efforts are fully structurally enabled and are focused on demonstrating changes in BH4-related biomarkers that correlate with drug pharmacokinetics and efficacy in preclinical animal models. The company was founded by Kevin Pojasek, Kai Johnsson, and Clifford Woolf in 2013 and is headquartered in Cambridge, MA. | Health Technology |
Neuromed Pharmaceuticals Ltd.
 Neuromed Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Neuromed Pharmaceuticals Ltd. develops chronic pain drugs. Its NMED-1077 product is an extended release formulation of hydromorphone in phase 3 clinical development. It conducts research for drugs to cure anxiety, epilepsy, hypertension, and cardiovascular diseases. The company was founded by Dr. Terrance P. Snutch in 1998 and is headquartered in Vancouver, BC. | Health Technology |
Brighton Biotech, Inc.
Brighton Biotech, Inc. BiotechnologyHealth Technology Brighton Biotech, Inc. provides medical research services. It specializes in acquiring and developing pharmaceutical and biotechnology products intended for the treatment and prevention of serious unmet medical needs. The company was founded in 2010 and is headquartered in New York, NY. | Health Technology |
CoLucid Pharmaceuticals, Inc.
 CoLucid Pharmaceuticals, Inc. BiotechnologyHealth Technology CoLucid Pharmaceuticals, Inc. engaged in the development of therapeutics for neurological disorders. Its products included Lasmiditan, a neurally acting anti-migraine agent that is designed to delivered efficacy in migraine without the vasoconstrictor activity associated with previous generations of migraine therapies and a Conjugated Stigmines platform that has generated a series of preclinical candidates for the chronic pain, Alzheimer's disease and psychiatric disorders. The company was founded by James F. White and Arthur M. Pappas in 2005 and was headquartered in Cambridge, MA. | Health Technology |
BlackThorn Therapeutics, Inc.
 BlackThorn Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Blackthorn Therapeutics, Inc. manufactures and markets medicines for neuro developmental disorders. The company is headquartered in San Francisco, CA. | Health Technology |
Nabriva Therapeutics GmbH
 Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | Health Technology |
Novelion Therapeutics, Inc.
 Novelion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelion Therapeutics, Inc. engaged in the development and commercialization of pharmaceuitical products. It focused in providing new standards of care for individuals living with rare diseases. The company was founded on February 3, 1981 and was headquartered in Vancouver, Canada. | Health Technology |
Tremeau Pharmaceuticals, Inc.
 Tremeau Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tremeau Pharmaceuticals, Inc. engages in the developing and delivering of non-opioid pain therapies. The firm product includes TRM-201 (rofecoxib). The company was founded by Bradford C. Sippy and Mark H. N. Corrigan in 2016 and is headquartered in Concord, MA. | Health Technology |
Perseus Holdings USA LLC
Perseus Holdings USA LLC Electronics DistributorsDistribution Services Perseus Holdings USA LLC markets vaccine platform technology. The company is headquartered in Austin, TX. | Distribution Services |
Exacis Biotherapeutics, Inc.
Exacis Biotherapeutics, Inc. Medical/Nursing ServicesHealth Services Part of Eterna Therapeutics, Inc., Exacis Biotherapeutics, Inc. is a development stage immuno-oncology company based in Cambridge, MA. Exacis uses its proprietary-based technologies to engineer next generation off-the-shelf NK and T cell therapies aimed at liquid and solid tumors. Exacis has an exclusive license to the Factor Bioscience technology for engineered NK and T cell products derived from iPSCs for use in oncology and holds all development and commercial rights for these investigational candidates. Exacis' approach avoids the use of DNA and viruses and instead uses a proprietary-based technology to generate iPSCs and to edit their genome to create stealthed, performance-enhanced allogeneic NK and T cell products, termed ExANK™, Exacar-NK™, and Exacar-T™ cells. The company was founded in 2020 by Gregory Fiore, Matthew Angel, James Pan. Gregory Fiore has been the CEO since 2020. Exacis Biotherapeutics was acquired by Eterna Therapeutics, Inc. on May 02, 2023 for $49 million. | Health Services |
Elios Therapeutics LLC
 Elios Therapeutics LLC Medical/Nursing ServicesHealth Services Part of Perseus Holdings USA LLC, Elios Therapeutics LLC is a biopharmaceutical company based in Austin, TX. The company is developing personalized therapeutic cancer vaccines using a proprietary particle delivery system to stimulate the immune system to recognize cancer cells as foreign pathogens and fight a patient's specific cancer. The company's lead therapeutic candidate is the TLPLDC vaccine, which targets unmet medical needs across a broad range of tumor types. | Health Services |
Wave Life Sciences USA, Inc.
Wave Life Sciences USA, Inc. Electric UtilitiesUtilities Part of Wave Life Sciences Ltd., Wave Life Sciences USA, Inc. is a company that provides nucleic acid therapeutics. The company is based in Cambridge, MA. The company was founded in 2012 by Gregory L. Verdine, Takeshi Wada. The CEO is Paul B. Bolno. | Utilities |
Silver Creek Pharmaceuticals, Inc.
Silver Creek Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Silver Creek Pharmaceuticals, Inc. develops novel regenerative medicines. The firm focuses on treating cardiovascular disease. Its molecules are designed to promote resilience and regeneration of damaged tissues after acute or chronic injury. The company was founded in 2010 and is headquartered in San Francisco, CA. | Health Technology |
